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Conditions for the equilibrium binding to opioid receptor of [3 H[sufentanil (/~ selective), [3H][D-Pen2,D-PenS]en- 
kephalin (5 selective), and [3H]U69,593 (x selective) were established in membranes from rat brain cerebrum, monkey 
cortex, or guinea pig cerebellum. The selectivity index of various opioid alkaloids and peptides in binding to the/z, 5, 
or x opioid receptors was expressed as the ratio of their ECs0 values in displacing two selective radiolabeled ligands: 
[ 3 H]sufentanil/[ 3 H](D.Pen 2,D_Pen 5 )enkephalin (selectivity: ~t/8), [ 3 H]sufentanil/[ 3 H]U69,593 (selectivity: ~/x), or 
[ 3 H][D.Pen 2,D.Pen 5 ]enkephalin/[ 3 H]U69,593 (selectivity: 8/x). High resolution in binding selectivity was observed: 
in rat brain the t~/6 selectivity for Tyr-D-Ala-Gly-(Me)Phe-Gly-ol and sufentanil were 0.02 and 0.03, whereas for 
[D-Pen2,D-PenS]enkephalin and ICI 174,864 they were 1 200 and 998. Compared to/z opiates, the specific binding of 
and x agonists was less sensitive to sodium. The results describe a routinely applicable methodological approach for 
the assessment of selective ligand binding to the/x, 6 and x opioid receptors in rodent and monkey brain membranes. 
Opioid binding selectivity; Brain membranes; [ 3 H]Sufentanil; [ 3 H][D-Pen 2,D-Pen 5 ]enkephalin; [ 3 H]U69,593; 
(Multiple opioid receptors) 
1. I n t r o d u c t i o n  
Characterization of opioid receptor heterogene- 
ity depends upon the availability of ligands with 
high selectivity toward the /~, 6 and K sites. In- 
deed, for a considerable time after the concept of 
multiple opioid receptors was introduced (Martin 
et al., 1976), progress in this field was hampered 
due to marginal selectivity of the then available 
opiates. Moreover, the use of opiates with cross- 
recognition at more than one receptor type has 
caused misinterpretations and disputes. A perti- 
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nent example is the benzomorphan derivative eth- 
ylketocyclazocine, included in numerous earlier 
studies as a x agonist. Binding studies with the 
radiolabeled form of this opiate have resulted in 
equivocal conclusions as to the existence of sep- 
arate K receptor sites (Hiller and Simon, 1979; 
Chang et al., 1980; Fischel and Medzihradsky, 
1981; Garzon et al., 1984). More recently, it was 
shown that this compound binds with appreciable 
affinities to all three, ~, 6 and x receptors in brain 
membranes from the rat (Gillan and Kosterlitz, 
1982; Fischel and Medzihradsky, 1986) and guinea 
pig (James and Goldstein, 1984). 
Extensive information on the receptor binding 
of various opiates, as they became available over 
the years, was provided by Kosterlitz and co- 
workers. Facing the lack of selective radiolabeled 
primary ligands, these authors used an excess of 
0014-2999/88/$03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division) 
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unlabeled selective opiates to block the unwanted 
binding component of the radioligand in competi- 
tive displacement assays (Gillan and KosteMitz, 
1982: Corbett et al., 1984). Another approach to 
gain specificity of opiate binding in membrane 
preparations is the selective alkylation of opioid 
receptors, either by the direct or protective ap- 
proach (James and Goldstein, 1984; Takemori and 
Portoghese, 1985; Clark and Medzihradsky, 1987). 
Ultimately, in such treated membranes containing 
only one type of functional opioid receptor any 
nonselective radiolabeled opiate, such as [3H] 
etorphine, can serve as a primary ligand to study 
the selectivity of other opiates (Medzihradsky, 
1987). However, successful alkylation still depends 
on the availability of selective irreversible and /o r  
reversible ligands. Nonetheless, using this ap- 
proach the binding selectivity of various opiates in 
guinea pig brain membranes was described, al- 
though the authors noted methodological limita- 
tions imposed by the approach (James and Gold- 
stein, 1984). The binding selectivity of opiates can 
also be studied in tissues specific for one type of 
opioid receptor, e.g., the ~ opioid receptor in 
guinea pig cerebellum (Robson et al., 1984; Clark 
et al., 1986). 
In this paper we report the use of the recently 
available highly selective radiolabeled ligands 
[3 H]sufentanil, [3 H](D_Pen2 D_Pen 5)enkephalin, 
and [3H]U69,593 to resolve and quantitate the 
binding of opiates to the/~, 6, and ~ receptors in 
unaltered brain membranes. In developing the 
binding assays, we have placed special emphasis 
on fulfilling the criteria essential for characterizing 
ligand-receptor interactions at equilibrium. Apply- 
ing the assays, we have determined the binding 
selectivity of 15 frequently used opiates. The re- 
suits contribute to the characterization of the tested 
compounds and, concurrently, the obtained ECs0 
values serve as pertinent references to evaluate the 
binding of novel opiates. While all the compounds 
were studied in rat brain membranes, the binding 
of selected opiates was also determined in 
membranes from monkey cortex, a tissue contain- 
ing /,, 6, and ~ opioid receptors (Mansour et al., 
1986b). In addition, the binding of putative 
opiates was assessed in membranes from guinea 
pig cerebellum. 
2. Materials and methods 
[3 H][D_Pen2,D_Pen 5]enkephalin (43 Ci/mmol)  
and [3H]U69,593 (42 Ci /mmol)  were purchased 
from New England Nuclear Corporation, and 
[3H]sufentanil (13.1 Ci /mmol)  was obtained from 
Janssen Pharmaceuticals. Tyr-D-Ala-Gly-(Me) 
Phe-Gly-ol was bought from Peninsula Laborato- 
ries, [D-Ser2,LeuS]enkephalin-Thr ~ from Cam- 
bridge Research Biochemicals, and U69,593 from 
the Upjohn Company. The other unlabeled opiates 
were obtained through the Opioid Basic Research 
Center at the University of Michigan. The pepti- 
dase inhibitors bestatin and L-leucyl-leucine were 
purchased from Sigma Chemical Company, 
captopril from Squibb and thiorphan from Cam- 
bridge Research Biochemicals. The other biochem- 
icals were obtained from Sigma. The chemical 
purity of all radiolabeled compounds was listed by 
the manufacturer as higher than 96%. This claim 
was confirmed in our laboratory by thin-layer 
chromatography in two different solvent systems 
recommended by the manufacturer. These de- 
terminations of purity were carried out at regular 
intervals throughout the study. 
Membranes from rat cerebrum, rhesus monkey 
cortex, and guinea pig cerebellum were prepared 
previously (Fischel and Medzihradsky, 1981; 
Medzihradsky et al., 1984). Briefly, the dissected 
tissue was washed in 50 mM Tris-HC1, pH 7.4, 
and disrupted for 1 min in 100 volumes of the 
ice-cold buffer, using a Polytron homogenizer, 
model PT-10, at power output 6.5. The homo- 
genate was centrifuged at 20000 × g for 15 min in 
the cold, and the obtained pellet resuspended with 
the original amount of buffer using a Dounce 
all-glass homogenizer. Aliquots of this suspension, 
sufficient for experiments on one given day, were 
frozen at - 7 0 ° C .  Prior to its use, the frozen 
suspension was quickly thawed, dispersed in a 
Dounce homogenizer and kept on ice. The protein 
concentration of the membrane suspensions was 
approximately 0.6 mg/ml  as determined by the 
method of Lowry et al. (1951), using bovine serum 
albumin as standard. 
The medium of the binding assay, in 8 ml 
polypropylene tubes, consisted of 400 btl mem- 
brane suspension (representing the linear range of 
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protein dependence as shown in fig. 1C), 50/~1 of 
50 m M  Tris-HC1, p H  7.4, or NaC1 solution to give 
a final concentra t ion of  150 m M  sodium, 50/~1 of 
tested compound  solution or water (for maximal 
binding), and 25 /~1 of radiolabeled opiate at the 
concentrat ions shown (table 1). Specific binding 
of  the radioligand was defined as the difference 
between binding in the absence and presence of  
an appropriate  excess of  the corresponding un- 
labeled opiate (fig. 1A, table 1). Cons tant  p H  
during the incubat ion was ascertained. After in- 
cubat ion at 2 5 ° C  to reach binding equilibrium 
(fig. 1B), the samples were filtered through glass 
fiber disks (Whatman  GF-C)  which were initially 
washed in water and then treated on a filter 
assembly with water saturated with N-amyl  al- 
cohol (Medzihradsky, 1976). The filtered samples 
were quickly washed with ice-cold 50 m M  Tris- 
HC1, pH  7.4, and placed into polyethylene count-  
ing vials. After  the addit ion of 1 ml of absolute 
ethanol and 10 ml xylene-dioxane-naphtalene- 
based scintillation fluid, the radioactivity of  the 
samples was determined by liquid scintillation 
counting. The average count ing efficiency, de- 
termined by [3H]H20,  was 54%. The experiments 
with opioid peptides were carried out both in the 
absence and presence of  peptidase inhibitors: 10 
/~M bestatin, 0.3 /aM thiorphan, 10 /~M captopril  
and 2 m M  L-leucyl-leucine (Corbett  et al., 1984). 
The affinity of the investigated ligands in bind- 
ing to opioid receptor  was expressed as the 
concentra t ion that inhibited 50% of maximal bind- 
ing of a given radiolabeled ligand (ECs0). The 
ECs0 value was determined by linear regression 
f rom plots relating inhibition of  specific binding 
in probit  units (Goldstein,  1974) to the log of  five 
different l igand concentra t ions  (fig. 2). The corre- 
lation coefficient of  the log-probit  plot (r z) was 
higher than 0.98 in all cases. S tandard  deviations, 
characteristic for each of  the three established 
assays, are listed in tables 2 and 3. Binding selec- 
tivity (selectivity index) was expressed as the ratio 
of  ECs0 values of a c o m p o u n d  in inhibiting the 
specific binding of two selective radiolabeled 
ligands, e.g., [3H]sufentanil and [3H][D-PenZ,D - 
Pen 5 ]enkephalin. 
3 .  R e s u l t s  
In the course of developing the three binding 
assays, several factors which influence ligand-re- 
ceptor  interaction were considered. The radio- 
labeled ligands were employed at concentrat ions 
(table 1) lower than the ECs0 values displayed by 
their unlabeled forms in inhibiting corresponding 
radioligand binding (tables 2 and 3). As the 
concentra t ion of radioligand increases relative to 
TABLE 1 
Experimental conditions for the 
methods. 
opioid receptor binding assays. The experimental procedure is described under Materials and 
Radioligand 
[ 3 H]Sufentanil 0.5 
[ 3 H]Sufentanil 0.5 
[ 3 H][D-Pen2,D-Pen5 ]enkephalin 1.5 
[ 3 H][D-Pen2,D-PenS ]enkephalin 1.5 
[ 3 H]Sufentanil 0.5 
[ 3 H]Sufentanil 0.5 
[ 3 H][D-Pen2,D-Pen5 ]enkephalin 1.5 




Radioligand NaC1 Equili- Membranes 
concentration (150#M) brium Source Protein 
(nM) reached (~g/assay) 
(min) 
+ 50 Rat 516 
- 50 Rat 387 
+ 60 Rat 516 
- 80 Rat 387 
+ 50 Monkey 164 
- 70 Monkey 164 
+ 60 Monkey 164 
- 70 Monkey 164 
- 40 Monkey 20 
+ 40 Guinea pig 16 
- 40 Guinea pig 16 
Displacing Specific binding 
unlabeled (fmol/mg (% of 
ligand protein) total 
( ~ M) binding) 
0.4 54 82 
0.4 72 81 
5.0 10 67 
5.0 14 68 
0.4 45 56 
0.4 71 69 
5.0 32 69 
5.0 43 72 
2.0 57 40 
2.0 134 62 
2.0 123 62 
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TABLE 2 
Inhibition of radiolabeled sufentanil and [D-PenZ,D-PenS]enkephalin binding in rat and monkey brain. In membranes from rat 
cerebrum and monkey brain cortex, the inhibition of specific equilibrium binding of 0.5 nM [3H]sufentanil or 1.5 nM [~H][D- 
Pen2,D-Pen 5]enkephalin by five different concentrations of the listed compounds was investigated in the presence and absence of 150 
mM NaC1. The ECs0 values were determined by linear regression analysis as described under Materials and methods. All regression 
coefficients (r 2) were higher than 0.98. The selectivity index was obtained by dividing the ECso values of a compound in inhibiting 
the binding of [3H]sufentanil and [3H][D-Pen2,D-PenS]enkephalin, respectively. For compounds with both ECs0s in the #M range 
(U50,488, U69,593), the selectivity indices are not listed (n.1.). All experiments were carried out in duplicate. Listed are either mean 
values and standard deviations of experiments repeated more than three times, or averages of two experiments with less than 10% 
difference between the respective ECs0 values. 
Compound [ 3 HlSufentanil [3 H][D-Pen 2~D-Pen 5 ]enkephalin 
ECs0 (nM) ECso ( + Na) ECs~ ~ (nM) ECs0 ( + Na) Selectivity 
(+NaCI)  EC50 ( - N a )  (+NaCI)  ECs0 ( - N a )  index 
( ~ / 6 )  
Rat cerebrum 
Tyr-D-Ala-Gly-(Me)Phe-Gly-ol 13.2 1.36 690 2.16 0.02 
Su fentanil 1.25 _+ 0.08 1.38 45.0 2.47 0.03 
Morphine 31.4 1.76 422 2.74 0.07 
/?-FNA 6.99 0.61 43.9 0.82 0.16 
/?-CNA 1.29 0.74 7.48 1.03 0.17 
Naloxone 6.37 0.49 14.3 0.52 0.44 
Etorphine 0.60 2.16 1.13 1.56 0.54 
Buprenorphine 1.07 0.73 1.12 0.95 (I.96 
Bremazocine 1.79 0.69 1.12 1.48 1.60 
Superfit 576 1.88 16.5 2.24 34.9 
[D-Ser 2,Leu 5 ]enkephalin-Thr 6 121_+16 0.68 1.05_+0.16 0.68 115 
ICI-174,864 58 900 _+ 9700 0.25 59.0 0.08 998 
[D-Pen2,D-Pen 5 ]enkephalin 7 720 _+ 320 0.76 6.44 _+ 0.67 0.98 1 200 
U50,488 7 230 13100 n.1. 
U69593 38 000 13 400 n.l. 
Monkey cortex 
Sufentanil 1.18_+0.35 1.96 81.1 _+15.0 2.16 0.01 
[D-Pen2,D-Pen 5 ]enkephalin 18 900 _+ 2 700 1.20 4.21 + 0.47 0.81 4 490 
U69,593 10700 17000 n.1. 
its K a, the deviation of the obtained ECs0 values 
from the actual K i increases (e.g., Bennett, 1978). 
In rat brain membranes, the K d S  for [3H]sufentanil 
and [ 3 H][D_Pen 2,D_Pen 5 ]enkephalin binding were 
0.9 nM and 4.2 nM, respectively (Remmers and 
Medzihradsky, 1987). In previous reports, the K d 
values for [3H]sufentanil binding in membranes 
from rat forebrain (Leysen et al., 1983), and for 
[3H][D_Pen 2,D_Pen 5]enkephalin binding in slide- 
mounted sections of rat brain (Mansour et al., 
1986a) were 0.3 nM and 8.0 nM, respectively. In 
membranes from rat brain and guinea pig cerebel- 
lum, the corresponding K d S  for [3H]U69,593 
binding (without NaC1) were 4 nM and 0.9 nM 
(Lahti et al., 1985). Thus, in rat brain membranes 
(table 2), the approximate ratios of K d to  em- 
ployed radioligand concentration were 1.8, 2.8 and 
2.6 for [3H]sufentanik [3H][D-Pen2,D-PenS]en- 
kephalin and [3H]U69,593, respectively. 
As illustrated for [3H]sufentanil (fig. 1), the 
concentration of unlabeled ligand employed to 
determine specific binding of the radioligand, and 
the dependence on time and protein of specific 
ligand binding at equilibrium were assessed for 
each of the three binding assays (table 1). The 
concentrations of unlabeled opiates (table 1) re- 
flect maximal displacement of the respective ra- 
dioligand (fig. 1A). Also confirmed was the unal- 
tered radiochemical purity of the radioligands 
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Fig. 1. Characteristics of [3H]sufentanil binding in rat brain. In 
suspensions of rat cerebral membranes the binding of 0.5 nM 
[3H]sufentanil in the presence of increasing concentrations of 
unlabeled sufentanil was determined following incubation for 
50 min at 25 o C (panel A). Specific binding was defined as the 
difference between [3H]sufentanil bound in the absence of 
unlabeled sufentanil and in the presence of sufficient sufentanil 
to cause maximal inhibition of the radiolabeled ligand. The 
specific binding of 0.5 nM [3H]sufentanil was determined after 
various times of incubation at 25°C  (panel B), and in the 
presence of increasing concentrations of membrane protein 
following incubation for 50 min at 25 ° C (panel C). Shown are 
averages of two experiments, run in duplicate. 
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placed on measuring ligand-receptor interactions 
under well defined equilibrium conditions: con- 
stant temperature of the samples was maintained 
throughout the incubation and filtering. Control 
experiments showed that placing the tubes in ice 
before filtering decreased the temperature of the 
assay suspension to 2°C in 10 min, and below 
1°C in 25 min. During that time, specific binding 
of [3H]sufentanil decreased by 17 and 29%, re- 
spectively (data not shown). The lack of peptidase 
action during the experiments was ascertained by 
the use of the enzyme inhibitors bestatin, captopril 
and thiorphan (and L-leucyl-leucine) at concentra- 
tions as described (Corbett et al., 1984). 
Under the employed experimental conditions 
(table 1), the extent specific binding and the ratio 
of total to specific binding of [3H]sufentanil and 
[3H][D-Pen2,D-PenS]enkephalin in rat and monkey 
brain membranes were favorable for use in 
routinely applicable binding assays. However this 
was not the case for [3H]U69,593: at 1-2 nM 
concentrations the extent of specific binding was 
marginal and resulted in a non-linear protein de- 
pendence above 5 /zg membrane protein, corre- 
sponding to approximately 50 cpm. Moreover, in 
monkey cortex the binding assay was imple- 
mented only in the absence of NaC1 in order to 
improve the statistical significance of the data: 
even without sodium the specific binding of 
[3H]U69,593 represented only 44% of total bind- 
ing (table 1). The results obtained with monkey 
brain were substantiated by the data on 
[3H]U69,593 binding in membranes from guinea 
pig cerebellum, a tissue containing predominantly 
opioid receptors (Robson et al., 1984). In these 
membranes, specific binding amounted to 62% of 
total binding (table 3), and B .... was similar to the 
value reported for homogenates of guinea pig brain 
(Lahti et al., 1985). The latter publication con- 
tained no information on the extent specific bind- 
ing. 
Whereas in rat brain membranes the inhibition 
of [3H]sufentanil (fig. 2) and [3H][D-Pen2,D- 
PenS]enkephalin binding by various opioids, in- 
cluding alkaloids, peptides, agonists, mixed 
agonists and antagonists was determined (table 2), 
the restricted supply of monkey brain membranes 
limited our investigation in this tissue to the three 
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TABLE 3 
Inhibition of radiolabeled U69,593 binding in monkey and 
guinea pig brain. In membranes from monkey brain cortex and 
guinea pig cerebellum, the inhibition of the specific equi- 
librium binding of 1.5 nM [3H]U69,593 by five concentrations 
of the listed opiates was investigated in the absence of NaC1. 
The ECs0 values were determined by linear regression from log 
concentration-probit plots of the data as described under 
Materials and methods. All regression coefficients were higher 
than 0.96. The selectivity indices were obtained by dividing the 
ECs0 values of a compound in inhibiting the binding of 
[3H]sufentanil and [3H]U69,593 (/L/K index) or the binding of 
[ 3 H][D.PenZ,D.Pen 5 ]enkephalin and [ 3 H]U69,593 (8 /~  index), 
respectively. Shown are either mean values and standard devia- 
tions of experiments repeated more than three times, or aver- 
ages of two experiments, all carried out in duplicate. 
Compound ECso Selectivity index 
(nM) ( # / ~ )  (8/K) 
Monkey cortex 
U69,593 8.41 + 2.08 
Sufentanil > 10000 
[D-PenZ,D-PenS]enkephalin > 10000 
Guinea pig cerebellum 
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opiates used as radiolabeled primary ligands (ta- 
bles 2 and 3). In membranes from guinea pig 
cerebellum the experiments focused on the bind- 
ing of putative ~ opioids, but also included, as a 
control, the assessment of the highly selective /~ 
and 6 opiates sufentanil and [D-Pen2,D-PenS]en - 
kephalin (table 3). 
In presenting the data we gave preference to 
the ECs0 values obtained in the presence of sodium 
(table 2), a condition that reflects, in part, the 
extracellular environment of the receptor. The ef- 
fect of NaC1 on /~ and 6 ligand binding was 
similar in rat and monkey membranes. Relative to 
the assay with sodium, in the absence of the ion 
the extent of specific binding of the agonist [3 H] 
sufentanil increased by 22 and 25% in rat and 
monkey membranes, respectively. The correspond- 
ing values for [3H][D-Pen2,D-PenS]enkephalin 
were 25 and 28% (table 1). Sodium downshifted 
the ECs0 values of the # agonists sufentanil, 
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Fig. 2. Inhibition of specific [3H]sufentanil binding in rat 
brain. Rat cerebral membranes were incubated with 0.5 nM 
[3H]sufentanil for 40 min at 2 5 ° C  in the absence of sodium 
with sufentanil (I),  Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (~), (D- 
Ser2,LeuS)enkephalin-Thr6 (e), and (D-Pen2,D-PenS)enkepha - 
lin (©), at concentrations as indicated. Plotted is the extent 
inhibition (in percent and probit units) of maximal specific 
binding of [3H]sufentanil against the log concentration of the 
tested opiates. The log-probit plots were obtained from linear 
regression analyses yielding the correlation coefficients depicted 
in the figure. Shown are results of representative experiments 
carried out in duplicate and repeated three to four times. 
morphine and Tyr-D-Ala-Gly-(Me)Phe-Gly-ol 
more than those of the 6 agonists [D-Pen2,D - 
PenS]enkephalin and [D-Ser2,LeuS]enkephalin (ta- 
bles 1 and 2). The specific binding of the x agonist 
[3H]U69,593 was also characterized by a relatively 
small sodium response (tables 1 and 3): the ECs0 
of its inhibition by U69,593 in the presence of 150 
mM NaC1 was 4.69 nM. It is of interest that the 
ECs0s of both naloxone and the 6 selective 
antagonist peptide ICI 174,864 (Cotton et al., 
1984) were strongly affected by sodium (table 2). 
Relative binding selectivity of a tested com- 
pound was expressed as the ratio of its ECs0s in 
inhibiting the binding (fig. 2) of two selective 
radioligands, e.g. [3H]sufentanil and [3HI[D- 
Pen 2,D-Pen 5]enkephalin (selectivity index: ~t/6). 
The selectivity of a compound was independent of 
its binding affinity, e.g., Tyr-D-Ala-Gly-(Me)Phe- 
Gly-ol and sufentanil showed similar/~ selectivity, 
although their binding affinities at the/~ receptor 
were markedly different. In rat membranes the 
selectivity indices ranged from 0.02 and 0.03 for 
Tyr-D-Ala-Gly-(Me)Phe-Gly-ol and sufentanil, the 
most # selective compounds, to 1200 for [D- 
Pen2,D-Pen 5]enkephalin, representing the highest 
6 selectivity (table 2). Whereas selectivity indices 
below 0.5 and above 1.6 reflected preferential 
recognition at t~ and 8 sites, respectively, values 
between these margins identified nonselective 
opiates such as etorphine, buprenorphine and 
bremazocine. Among the antagonists, ICI 174,864 
exhibited high 8 selectivity with an index of 998, 
while naloxone was relatively nonselective. Of the 
three 'irreversible' opioid ligands, superfit (Smith 
et al., 1985; Clark and Medzihradsky, 1986) had 
considerable 8 selectivity, while/~-funaltrexamine 
(/3-FNA) and /~-chlornaltrexamine (/~-CNA) 
(Ward et al., 1982) showed preference toward t~ 
sites. In monkey cortical membranes the selectivi- 
ties of sufentanil and [D-Pen2,D-PenS]enkephalin 
were even more pronounced than in rat brain 
(table 2). 
While the putative ~ opiates U50,488 (Von 
Voigtlander et al., 1983) and U69,593 (Lahti et al., 
1985) were not recognized at t~ and 6 sites in rat 
brain (table 2), they inhibited the binding of 
[3H]U69,593 with high potency in guinea pig 
cerebellum or monkey cortex (table 3). Bremazo- 
cine inhibited the binding of [3H]U69,593 in 
guinea pig cerebellum with a low ECs0, but it also 
bound with high affinity to /~ and 6 sites in rat 
brain. Sufentanil and [D-Pen2-D-PenS]enkephalin 
were rejected from sites labeled by [3H]U69,593 in 
monkey brain and guinea pig cerebellum (table 3). 
4. Discussion 
The availability of the highly selective/~, 8 and 
opiates sufentanil (Leysen et al., 1983), [D- 
PenZ,D-Pen 5 ]enkephalin (Mosberg et al., 1983) and 
U69,593 (Lahti et al., 1985) as radiolabeled ligands 
enabled us to investigate the selectivity of various 
opiates in direct binding assays without the use of 
protective ligands (e.g., Gillan and Kosterlitz, 
1982) or initial alkylation (James and Goldstein, 
1984), approaches which carry the risk of incom- 
plete receptor protection or receptor alteration. It 
is of interest that insufficient ligand binding fol- 
lowing protective receptor alkylation with/~-CNA 
prevented the assessment of opioid binding selec- 
tivity in an artificial extracellular medium (James 
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and Goldstein, 1984). In our work, selective un- 
labeled opiates such as Tyr-D-Ala-Gly-(Me)Phe- 
Gly-ol, ICI 174,864 and U50,488 served as perti- 
nent reference compounds in evaluating the bind- 
ing of other opiates to the sites labeled by the 
three radioligands. The results on the inhibition of 
radioligand binding were purposefully presented 
as ECs0 s rather than the, theoretically more accu- 
rate, K i values. The approach taken simplifies the 
comparison with pertinent data on the receptor 
binding of novel opiates, frequently presented as 
ECs0s (e.g., Woods et al., 1979; Woods et al., 
1987). Furthermore, the binding assays in the pre- 
sent work were carried out under experimental 
conditions which minimize the difference between 
the obtained ECs0 values and the corresponding 
Kis (fig. 1, table 1), parameters linked by the 
relationship K i=  ECs0/[1 + ( L / K  d)] (Cheng and 
Prusoff, 1973). 
Our original goal was to compare the binding 
selectivity of distinct opiates in membranes from 
rat and monkey brain. However, the limited den- 
sity of binding sites for [3H]U69,593 in rat brain 
membranes made this tissue unsuitable for the 
routine assessment of ~ ligand binding. To sup- 
port the data obtained with monkey membranes, 
the study was expanded to include guinea pig 
cerebellum, a tissue containing predominantly 
opioid receptors as reflected in ligand binding 
(Robson et al., 1984) and receptor-G-protein cou- 
pling (Clark et al., 1986). Our selection of monkey 
brain cortex was guided by its content of/~, 6 and 
K opioid receptors (Mansour et al., 1986b) and, 
considering possible application in routine assays, 
by the large quantity of this tissue. Indeed, accord- 
ing to the results of this study, membranes from 
monkey cortex appear to be an interesting alterna- 
tive to rat brain membranes in investigating the 
interaction of opioid ligands with multiple opioid 
receptors (Medzihradsky, 1987). 
The present investigation confirmed the dif- 
ferential sensitivity of ~t and 8 ligand binding 
towards extracellular concentrations of NaC1 
(Paterson et al., 1986). This difference was 
observed both in rat and monkey brain mem= 
branes. We have previously described the resolu- 
tion of /x and ~ receptor binding on the basis of 
smaller responses of ~ agonists to sodium 
350 
(Medzihradsky et al., 1984), a property displayed 
in this study by [3H]U69,593 binding as well. 
The obtained selectivity indices in rat brain 
clearly identified opiates with h igh/ ,  and 6 selec- 
tivity. The indices of less selective compounds 
underlined the necessity to carefully analyze the 
ECs0s used for their computation; e.g. [D-Ser 2, 
LeuS]enkephalin-Thr 6, a putative 6 agonist (David 
et al., 1982), had a relatively low selectivity index, 
# /6  of 115 although it inhibited [3H][D-Pen2,D- 
PenS]enkephalin binding with an EC50 of 1.05, a 
potency five times higher than that of [D-Pen2,D- 
PenS]enkephalin. However, [D-Ser2,LeuS]enke - 
phalin-Thr 6 was recognized at ~t sites with a 64- 
fold higher affinity than [D-PenZ,D-Pen 5] 
enkephalin (table 2). Considering the binding pro- 
file of the putative K agonist bremazocine, there 
seems to be little advantage of its use to label K 
sites over that etorphine, a recognized nonselective 
opiate. In contrast, the true K ligands U50,488 and 
U69,593, showed rejection by the ~t and 8 recep- 
tors. 
The binding assay with [3H]U69,593 as the 
primary ligand now allows the accurate assess- 
ment of ligand interaction with the K opioid recep- 
tor. The binding profile of putative K opiates in 
monkey brain cortex and guinea pig cerebellum 
confirmed the superior K selectivity of U50,488 
and U69,593. In both membrane preparations, 
sufentanil and [D-Pen2,D-Pen 5 ]enkephalin, but not 
bremazocine, were excluded from sites labeled by 
[3H]U69,593. In membranes from rat cerebrum 
the binding assay was not established due to the 
low density of ~ sites. In that respect, it is of 
interest that in rat brain slices mounted for auto- 
radiography, the ECs0 for U50,488 was 179-fold 
higher than that of bremazocine in displacing 
[3H]bremazocine (Mansour et al., 1986a). 
Notwithstanding the inclusion in our study of 
novel opioid ligands in tritiated or unlabeled form, 
the findings of this work are in general agreement 
with the selectivity of opiates described in rat 
brain and guinea pig ileum using, in part, ligand 
protection to counter cross-reactivity of the radio- 
labeled primary ligands (Gillan and Kosterlitz, 
1982; Corbett et al., 1984). Our data also support 
the ranking of Tyr-D-Ala-Gly-(Me)Phe-Gly-ol and 
sufentanil ,  [D-PenZ,D-Pen 5]enkephalin, and 
U50,488 as highly selective ~t, & and ~ opiates, 
respectively, following receptor alkylation in 
guinea pig brain membranes (James and Gold- 
stein, 1984), although diverging selectivities for the 
8 antagonist analogues ICI 174,864 (Cotton et al., 
1984) and ICI 154,129 (Shaw et al., 1982) were 
obtained in the two studies. The binding selectivi- 
ties described in this paper corraborate those dis- 
played by opioid agonists and antagonists in the 
course of receptor-mediated stimulation of brain 
GTPase (Clark and Medzihradsky, 1987). The 
similarity of results obtained by different methods 
validates the direct approach applied in this study 
based on the equilibrium binding of three highly 
selective radiolabeled ligands. These assays are 
now being used to guide the synthesis of novel 
selective opiates (Mosberg et al., 1987). It will be 
of interest to compare the selectivity profile 
described here with that obtained by inhibiting the 
binding of the nonselective ligand [3H]etorphine 
in membranes made specific for a given type of 
opioid receptor by selective alkylation (Medzih- 
radsky, 1987). 
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